TiVenture SA
TiVentures SA is a seed investment fund established in 2016, owned by Fondazione Centenario Banca Stato, focusing on early-stage companies with innovative technologies and high growth potential.
Funder analysis
Web-researched analysis· 25 Jul 2026· v7What they fund
Seed rounds for early-stage companies in southern Switzerland, with cheque sizes ranging from CHF 550k to CHF 3.5M [1]. Follow-on investments in Series A and B rounds, such as xFarm's CHF 17M Series B [1].
Investment thesis
TiVenture operates as a seed investment fund focused on backing early-stage companies possessing innovative technologies and high growth potential. The fund is geographically concentrated, primarily investing in startups located in southern Switzerland.
- Sector focus — The fund is mainly active in life science, medical, high-tech and IT sectors [1].
- Geographic mandate — Principally invests in Ticino-based companies to contribute to the growth, diversification and innovation of the economy in the Ticino territory [1].
- Stage specificity — Invests in early-stage companies, primarily seed rounds, with follow-on participation in Series A and B rounds [1].
- Portfolio performance — Portfolio companies have aggregate annual revenues exceeding CHF 35 Mio (average of 30% increase annually) and a total number of employees exceeding 390 [1].
Interconnection: The focus on life sciences and high-tech in southern Switzerland aligns with the managing partners' deep expertise in biomedical and high-tech areas.
- Sector focus — The fund is mainly active in life science, medical, high-tech and IT sectors [1].
- Geographic mandate — Principally invests in Ticino-based companies to contribute to the growth, diversification and innovation of the economy in the Ticino territory [1].
- Stage specificity — Invests in early-stage companies, primarily seed rounds, with follow-on participation in Series A and B rounds [1].
- Portfolio performance — Portfolio companies have aggregate annual revenues exceeding CHF 35 Mio (average of 30% increase annually) and a total number of employees exceeding 390 [1].
Interconnection: The focus on life sciences and high-tech in southern Switzerland aligns with the managing partners' deep expertise in biomedical and high-tech areas.
Value add
Hands-on support from managing partners with deep industry expertise in biomedical and high-tech areas [1]. Access to a network of co-investors and strategic partners [1].
Fit verdict: Ideal for founders in life sciences or high-tech seeking seed funding and strategic guidance in southern Switzerland.
Founder diligence script:
- What is the expected follow-on investment capacity for this fund?
- How does TiVenture leverage its network of co-investors for subsequent rounds?
- What is the typical decision-making timeline for seed investments?
Portfolio focus
The portfolio clusters around life sciences (Gain Therapeutics, IBI SA), high-tech (xFarm, Delvitech), and IT (Artificialy, BigOmics Analytics) [1].
Notable investments & exits
Sailogy (2018) [1]. 99 Technologies SA (2020) [1]. Gain Therapeutics IPO on NASDAQ (2021) [1].
Strategic implications
TiVenture's edge lies in its deep industry expertise and strong network in southern Switzerland's life sciences and high-tech sectors. A key risk is its geographic concentration, which may limit deal flow and diversification. The signal that would change the read is a shift in investment focus beyond southern Switzerland or a significant expansion into new sectors.
Where they could go further
Consider expanding the geographic focus to attract a broader range of high-potential startups. Develop a more structured approach to follow-on investments to support portfolio companies through later stages. Enhance the value proposition for founders by offering more hands-on support in areas like go-to-market strategy and international expansion.